MYLAN-NAPROXEN/ESOMEPRAZOLE MR TABLET (IMMEDIATE AND DELAYED-RELEASE)

Land: Kanada

Sprache: Englisch

Quelle: Health Canada

Wirkstoff:

NAPROXEN; ESOMEPRAZOLE (ESOMEPRAZOLE MAGNESIUM)

Verfügbar ab:

MYLAN PHARMACEUTICALS ULC

ATC-Code:

M01AE52

INN (Internationale Bezeichnung):

NAPROXEN AND ESOMEPRAZOLE

Dosierung:

500MG; 20MG

Darreichungsform:

TABLET (IMMEDIATE AND DELAYED-RELEASE)

Zusammensetzung:

NAPROXEN 500MG; ESOMEPRAZOLE (ESOMEPRAZOLE MAGNESIUM) 20MG

Verabreichungsweg:

ORAL

Einheiten im Paket:

60/100/500

Verschreibungstyp:

Prescription

Therapiebereich:

OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS

Produktbesonderheiten:

Active ingredient group (AIG) number: 0252870002; AHFS:

Berechtigungsstatus:

APPROVED

Berechtigungsdatum:

2017-02-08

Fachinformation

_ _
_MYLAN-NAPROXEN / ESOMEPRAZOLE MR (Naproxen / Esomeprazole Modified
Release Tablets) _
_Page 1 of 65_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
Pr
MYLAN-NAPROXEN / ESOMEPRAZOLE MR
Naproxen / Esomeprazole (as esomeprazole magnesium)
Modified release tablets, 375 mg naproxen / 20 mg esomeprazole and 500
mg naproxen / 20 mg
esomeprazole, Oral
NSAID and H
+
, K
+
-ATPase Inhibitor
Mylan Pharmaceuticals ULC
85 Advance Road
Etobicoke, Ontario
M8Z 2S6
Date of Initial Authorization:
FEB 08, 2017
Date of Revision:
JUL 04, 2023
Submission Control Number: 273201
_ _
_MYLAN-NAPROXEN / ESOMEPRAZOLE MR (Naproxen / Esomeprazole Modified
Release Tablets) _
_Page 2 of 65_
RECENT MAJOR LABEL CHANGES
3 SERIOUS WARNINGS AND PRECAUTIONS BOX
07/2023
7 WARNINGS AND PRECAUTIONS, Monitoring and Laboratory Tests
07/2023
7 WARNINGS AND PRECAUTIONS, Skin
07/2023
7 WARNINGS AND PRECAUTIONS, 7.1 Special Populations
07/2023
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL CHANGES
...........................................................................................
2
TABLE OF CONTENTS
.............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
.....................................................................
4
1
INDICATIONS
..............................................................................................................
4
1.1 Pediatrics
....................................................................................................................
4
1.2 Geriatrics
....................................................................................................................
4
2
CONTRAINDICATIONS
.................................................................................................
4
3
SERIOUS WARNINGS AND PRECAUTIONS BOX
............................................................ 5
4
DOSAGE AND ADMINISTRATION
.